CLIMB THAL-111/SCD-121: Phase I/II Studies of CTX001 for Transfusion-Dependent β-Thalassemia and Sickle Cell Disease

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Among the first 10 study participants with ≥ 3 months of follow-up, CTX001 infusion achieved cessation of pRBC transfusions for TDT patients, and eliminated veno-occlusive events for severe SCD patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 233 KB
Released: December 16, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Downloadable summary slideset from a live ASH 2021 satellite symposium on optimizing outcomes in hemophilia A with factor and nonfactor therapy from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Mark Reding, MD Guy A. Young, MD
Released: December 21, 2021

Efficacy and safety in the ATLAS-INH trial of fitusiran for hemophilia A or B with inhibitors presented at ASH 2021, as reported by Clinical Care Options (CCO)

Released: December 21, 2021

A brief summary slideset from an ASH 2021 satellite symposium on the application of new guidelines in aTTP, from Clinical Care Options (CCO)

Paul Coppo, MD, PhD Marshall Mazepa, MD Ara Metjian, MD Released: December 20, 2021

Phase II results of abatacept in patients with steroid-refractory chronic GVHD from ASH 2021, as reported by Clinical Care Options (CCO)

Released: December 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings